19.78 USD
-0.6 (-2.94%)
19.64 USD
-0.14 (-0.71%)
ADMA gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make ADMA a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in 4 of the past 5 years.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of ADMA (36.83%) is better than 98.68% of its industry peers.
ADMA's Return On Equity of 48.57% is amongst the best of the industry. ADMA outperforms 98.68% of its industry peers.
ADMA has a Return On Invested Capital of 25.76%. This is amongst the best in the industry. ADMA outperforms 98.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 42.87%, ADMA belongs to the top of the industry, outperforming 97.93% of the companies in the same industry.
ADMA's Operating Margin of 34.19% is amongst the best of the industry. ADMA outperforms 97.36% of its industry peers.
With a decent Gross Margin value of 54.71%, ADMA is doing good in the industry, outperforming 76.65% of the companies in the same industry.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
ADMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADMA has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 22.58 indicates that ADMA is not in any danger for bankruptcy at the moment.
ADMA has a Altman-Z score of 22.58. This is amongst the best in the industry. ADMA outperforms 90.96% of its industry peers.
ADMA has a debt to FCF ratio of 1.78. This is a very positive value and a sign of high solvency as it would only need 1.78 years to pay back of all of its debts.
The Debt to FCF ratio of ADMA (1.78) is better than 93.60% of its industry peers.
ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
ADMA has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: ADMA underperforms 66.10% of its industry peers.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 22.58 |
ROIC/WACC2.92
WACC8.82%
2.3 Liquidity
ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.13, ADMA is doing good in the industry, outperforming 70.43% of the companies in the same industry.
A Quick Ratio of 3.65 indicates that ADMA has no problem at all paying its short term obligations.
With a Quick ratio value of 3.65, ADMA perfoms like the industry average, outperforming 45.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 27.62%.
ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 33.90% on average per year.
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.48% yearly.
EPS Next Y19.68%
EPS Next 2Y36.5%
EPS Next 3Y36.8%
EPS Next 5Y33.9%
Revenue Next Year20.91%
Revenue Next 2Y22.61%
Revenue Next 3Y24.25%
Revenue Next 5Y21.48%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADMA is valuated quite expensively with a Price/Earnings ratio of 36.63.
Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 91.71% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.56, ADMA is valued a bit more expensive.
A Price/Forward Earnings ratio of 21.23 indicates a rather expensive valuation of ADMA.
94.35% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
ADMA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.63 | ||
| Fwd PE | 21.23 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.22% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 91.15% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 115.93 | ||
| EV/EBITDA | 26.96 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ADMA does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ADMA may justify a higher PE ratio.
ADMA's earnings are expected to grow with 36.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.86
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3Y36.8%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
19.78
-0.6 (-2.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.44%
Inst Owner Change5.68%
Ins Owners2.35%
Ins Owner Change-2.78%
Market Cap4.71B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts84
Price Target27.8 (40.55%)
Short Float %8.15%
Short Ratio5.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-6.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.66%
EPS NY rev (1m)-1.12%
EPS NY rev (3m)2.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.84%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.63 | ||
| Fwd PE | 21.23 | ||
| P/S | 9.64 | ||
| P/FCF | 115.93 | ||
| P/OCF | 72.46 | ||
| P/B | 10.92 | ||
| P/tB | 11.02 | ||
| EV/EBITDA | 26.96 |
EPS(TTM)0.54
EY2.73%
EPS(NY)0.93
Fwd EY4.71%
FCF(TTM)0.17
FCFY0.86%
OCF(TTM)0.27
OCFY1.38%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.86
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 22.58 |
F-Score7
WACC8.82%
ROIC/WACC2.92
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.68%
EPS Next 2Y36.5%
EPS Next 3Y36.8%
EPS Next 5Y33.9%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.91%
Revenue Next 2Y22.61%
Revenue Next 3Y24.25%
Revenue Next 5Y21.48%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.58%
EBIT Next 3Y47.86%
EBIT Next 5Y37.89%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 36.63 and the Price/Book (PB) ratio is 10.92.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.